GILD vs BMY — Key Metrics
| Metric | GILD (GILEAD SCIENCES INC) | BMY (BRISTOL MYERS SQUIBB CO) |
|---|---|---|
| Price | 149.05 | 62.4 |
| Market Cap | 184.82 Billion | 127.47 Billion |
| P/E (TTM) | -57.33 | 13.71 |
| P/B (Quarterly) | 13.717 | 5.936 |
| P/S (TTM) | 6.07 | 2.59 |
| Net Profit Margin (TTM) | -10.6 | 18.9 |
| Gross Margin (TTM) | 79.6 | 70.2 |
| ROE (TTM) | -16.3 | 46.8 |
| Revenue Growth YoY (TTM) | None | None |
Upfront Investment - S&P 500 Stock Comparison & AI Analysis
AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.
Performance Comparison
AI Model Recommendation
GILD · GILEAD SCIENCES INC
Outperform
BMY · BRISTOL MYERS SQUIBB CO
Outperform
Recommendation Summary
Both stocks are projected to outperform the market over the next year. If you have to make a choice, Upfront Recommendation: BMY.
Financial Metrics
Prices delayed ~15 min
| GILD | Metrics | BMY |
|---|---|---|
| $149.05 | Price | $62.40 |
| — | Market Capitalization | — |
| 6.07 | Price to Sales | 2.59 |
| 14.28 | Price to FCF Ratio | 11.14 |
| 7.62 | Price to Gross Profit | 3.69 |
| 30.47 | Price to R&D | 11.89 |
| 13.25 | Price to Current Assets | 4.46 |